Connect with us

Media & Technology

Cannagistics Inc (OTCMKTS: CNGT) Running Northbound as Co Readies New Product Line for Market & Global3PL Gains Traction

Published

on

Cannagistics Inc (OTCMKTS: CNGT) has seen a massive surge in volume and price in recent days skyrocketing out of the triple zeroes to recent highs of $0.024 per share. The stock is quickly getting noticed by investors and some big players in small caps who are accumulating at current levels. We previously reported on CNGT back on November 1, 2020 stating at the time: “Reverse Merger plays are some of the biggest runners in small caps rivaling only biotech’s in their ability to make historic shot term gains. CNGT has been heating up since the Company got new CEO Jam Rob Gietl on board who was most recently, Until March 2020 the Interim CEO of Availa Bio, Inc., a company engaged in the development of numerous patented and patent pending products in the health and wellness space. According to an 8k filed by PBIO; “Pressure BioSciences, Inc. entered into a binding letter of intent to merge with Cannaworx Holdings, Inc. Pursuant to the Second Amendment, the parties extended the September 30, 2020 deadline to October 31, 2020. 

It’s easy to see why investors are bidding CNGT Higher; pink current, the Company has a stellar management team behind it led by Jim Morrison was previously President of L’Oréal for 9 years, he acquired Redken and Matrix and led a top-line growth average above 20%.  They already have 4 products at market 2 of which were previously approved by the FDA and are currently launching a number of new products. They also own a valuable intellectual property portfolio with numerous patents and patents pending. CNGT has an excellent stock structure with 266,242,608 shares outstanding of which 94,097,582 are restricted leaving 172,327,026 free trading shares. CNGT trades at a total market capitalization of $3,274,784.  CNGT popped over $0.10 per share this time last year and investors are looking for a return to these levels and a break over. CNGT has liquidity, momentum and a growing shareholder base bidding the stock higher. 

Cannagistics, Inc. (OTC: CNGT) is a U.S. corporation that operates both general and specialty 3PLs (3rd party logistics) with a focus on supply chain management, reverse logistics, warehousing, and transportation, and currently developing industry-specific technology platforms. The Company owns a valuable intellectual property portfolio with numerous patents and patents pending. 

Global3PL (Ontario, Canada) is the Company’s general commodities operation, with warehouses in Canada and the U.S. that provide monthly and just-in-time inventory, pick and ship, custom house brokerage, as well as international freight forwarding, expedited and deferred air, local, regional, and North American consumer household pickup and delivery, less-than-truckload (“LTL”), truckload (TL). 

Cannagistics, Inc. (CNGT Canadian subsidiary) is a cannabis-specific logistics company aimed at streamlining the fragmented cannabis marketplace. The first Canadian company to obtain its own bonded warehouse license for cannabis, we’re also developing the most robust supply chain technology platform specifically for the cannabis ecosystem — to tap the enormous opportunities in the emerging global cannabis marketplace With an intent to solve pain points, we’ll use technology to streamline the complexities of coordinating compliance (state by state and country by country), logistics, international clearances, information, and product shelf-life tracking, powered by services by our knowledge-based operations team 

The Company has a stellar management team behind it; CEO Jim Morrison was previously President of L’Oréal for 9 years, he acquired Redken and Matrix and led a top-line growth average above 20%. As CEO, he headed the first celebrity-driven video shopping app in partnership with SPRINT; Graham Webb, one of the most successful startups in hair care; and Sexy Hair Concepts for four years. 

To Find out the inside Scoop on CNGT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CNGT

Dr. Babak “Bobby” Ghalili, DMD, is one of the foremost periodontal and reconstructive dental surgeons in the field, he is an Associate Professor of Periodontal Surgery at New York University and the University of Medicine and Dentistry of New Jersey. Dr. Ghalili is a graduate of Brandeis University, Tufts University, and UMDMJ, and author of 21 patents (6 awarded patents and 15 patent pending). 

On January 3 CNGT reported it is poised to start its marketing and promotion of its new product line in the 1st Quarter of 2022. 

The Company’s current products include: (there is an excellent listing of the Company’s products and patents in their most recent 10k)

ImmuniZinTM (Immune Booster) containing a FDA cleared formulation and ingredient for immune boosting and T-cell enhancement 

Canagel® – (Anhydrous Hydrogel Composition and delivery system). Revolutionary, patented, oral transmucosal delivery of CBD/Phycannabionoids in the form of an oral strip that melts in the mouth. 

Veterinary Cannabinoid and Menthol Compositions and Methods 

KidzStrips® – Thin Film Toothpaste Strip, United States Patent and European Patent 

HydroSoil® -Water retaining Hemp enhanced fertilizer, water plant once every two weeks 

IcyEase – Adhesive Ice Pack for muscle/joint pain to cool surface and address pain. 

Slim-D – Appetite-suppressant oral strip with 50 mg Hoodia & 10 mg Full Spectrum Phytocannabinoid 

Energy Lighting Strips – High caffeine fast dissolving oral energy strip with Matcha Green Tea and Hemp/Full Spectrum Phytocannabinoid 

Silverpro – Revolutionary technology combining genuine silver yarn with low-static carbon fibers, to create the world’s most advanced-compression pain relief fabric. 

Jim Morrison, President/CEO, stated, “I am extremely excited to bring these groundbreaking products to the market. My experience and background, along with the years of contacts, allow me to capitalize on the relationships developed over the years to assist the Company.” 

For more on CNGT subscribe Right Now!

CNGT has seen a massive surge in volume and price in recent days skyrocketing out of the triple zeroes to recent highs of $0.024 per share. The stock is quickly getting noticed by investors and some big players in small caps who are accumulating at current levels. We previously reported on CNGT back on November 1, 2020 stating at the time: “Reverse Merger plays are some of the biggest runners in small caps rivaling only biotech’s in their ability to make historic shot term gains. CNGT has been heating up since the Company got new CEO Jam Rob Gietl on board who was most recently, Until March 2020 the Interim CEO of Availa Bio, Inc., a company engaged in the development of numerous patented and patent pending products in the health and wellness space. According to an 8k filed by PBIO; “Pressure BioSciences, Inc. entered into a binding letter of intent to merge with Cannaworx Holdings, Inc. Pursuant to the Second Amendment, the parties extended the September 30, 2020 deadline to October 31, 2020.  It’s easy to see why investors are bidding CNGT Higher; “pink current” the Company has a stellar management team behind it led by Jim Morrison was previously President of L’Oréal for 9 years, he acquired Redken and Matrix and led a top-line growth average above 20%.  They already have 4 products at market 2 of which were previously approved by the FDA and are currently launching a number of new products. They also own a valuable intellectual property portfolio with numerous patents and patents pending. CNGT has an excellent stock structure with 266,242,608 shares outstanding of which 94,097,582 are restricted leaving 172,327,026 free trading shares. CNGT trades at a total market capitalization of $3,274,784.  CNGT popped over $0.10 per share this time last year and investors are looking for a return to these levels and a break over. CNGT has liquidity, momentum and a growing shareholder base bidding the stock higher. We will be updating on CNGT when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CNGT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CNGT either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.